Product Highlights Each vial contains 10 mL solution (~100 sprays) Each spray delivers 0.1 mL = 210 mcg total blend Blend Content per vial: PT-141 (10 mg), MT-2 (10 mg), Oxytocin (1 mg) Specialized pharmaceutical-grade nasal solution designed for comfort and ease on the nose Unlike many other nasal sprays, this formula avoids irritation and dryness Packaged in Class A, lead-free pharmaceutical glass bottles Tamper/Child-Proof Cap + Orifice Reducer for integrity, sterility, and ease of use Description Lust Mist Nasal Spray is studied for its synergistic action on melanocortin and oxytocin pathways
Consider Alternatives If Who Should Avoid Do not use if You have active cancer or a history of cancerIGF-1 can stimulate cell growth including potentially cancerous cells You are pregnant or breastfeedingeffects on fetal/infant development are unknown You have diabetic retinopathyIGF-1 may accelerate eye blood vessel growth You have uncontrolled diabetesblood sugar management becomes extremely difficult You are under 21can affect natural growth plate closure and hormonal development You've had allergic reactions to IGF-1 or similar peptides Use with caution if !You have any insulin resistance or pre-diabetesmonitor blood sugar very carefully !You take medications that affect blood sugar levelsinteractions can be dangerous !You have heart conditionsIGF-1 can cause cardiac tissue growth !You have kidney or liver issuesmay affect peptide metabolism !You have carpal tunnel syndromeIGF-1 can worsen symptoms !You have a family history of cancerdiscuss with your doctor first Administration How do I use it
Federal law defines drug shortage as a period of time when the demand or projected demand for the drug in the United States exceeds the supply, 21 USC 356c(h)(2), and FDA considers a shortage resolved when all the manufacturers are able to meet total national historical demand. This is the statutory authority upon which compounded copies of FDA approved GLP-1 drugs have proliferated in the United States creating greater access at a lower cost for patients, albeit with a greater safety risk than the approved, brand named versions
In this article, well explore the potential of GLP-1 patches, how they might fit into the broader treatment landscape, and what patients considering metabolic health support should know about the future of these therapies
These novel constructs represent the Company's first fully AI-generated assets, complementing their growing portfolio of AI-assisted and laboratory-developed therapies
All peptide therapy programs are based on provider evaluation, medical history, patient goals, and clinical appropriateness
